Latest News

New data on first-line oral therapies in MS

November 4, 2015

ECTRIMS highlights

Long-term data
Safety studies
Comment: Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada

The 31^st congress of the European Committee for Treatment and Research in MS (ECTRIMS) featured new research on current therapies for multiple sclerosis. In Canada, two oral therapies – teriflunomide and dimethyl fumarate (DMF) – are routinely used as first-line agents. The following summarizes key data for these two therapies presented at ECTRIMS. Read More

Late-breaking news at ECTRIMS 2015: ocrelizumab, minocycline and biotin

October 28, 2015

European Committee for Treatment and Research in MS (ECTRIMS) 31^st Congress – Barcelona, Spain, October 7-10, 2015 – The Late Breaking session at ECTRIMS 2015 was especially interesting this year as new data were presented on several novel MS treatments. Read More

Quality of life in schizophrenia: the QUALIFY trial

October 14, 2015

QUALIFY study
Commentary from Dr. Ofer Agid

Considerable advances have been made in recent decades in the management of schizophrenia. A majority of first-episode patients achieve remission of psychotic symptoms within the first year of treatment (Lieberman et al. Arch Gen Psychiatry 1993;50:369-376), and early recurrence rates are low (Zipursky et al. Schizophr Res 2014;152:408-414). Read More

Long-term outcomes of HSCT in MS

October 10, 2015

REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – The MS-AHSCT Long-Term Outcomes Study Group has compiled data for MS patients undergoing autologous hematopoietic stem cell transplantation (HSCT) during the period 1995-2006 to determine long-term outcomes (Muraro et al. ECTRIMS 2015; abstract 1671). A total of 281 patients from 25 centres were evaluable. The median duration of follow-up was 6.6 years (range 0.2-16 years). Read More